EKF: Resilient H1 2026 results, improved margins, and strong outlook driven by strategic execution
Revenue held steady at GBP 25 million in H1 2026, with gross margin up to 53% and adjusted EBITDA rising 2.4% to GBP 5.9 million. Operational progress included a key U.S. blood bank contract, a strategic rebrand, and targeted investments, supporting confidence in a strong H2 and full-year outlook.B…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.